OncoMatch/Clinical Trials/NCT05879653
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Is NCT05879653 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including MK-3475 and ASG-22CE for bladder cancer.
Treatment: MK-3475 · ASG-22CE — This study is designed to assess the efficacy and safety of induction therapy with MK-3475 and ASG-22CE and radiation therapy with MK-3475 in patients with cT2-4aN0M0 muscle invasive bladder cancer who are unfit for or refuse radical cystectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage MIBC, N0M0
first confirmed diagnosis of MIBC... Has clinically non-metastatic bladder cancer (N0M0) determined by imaging
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic/local radiation therapy
Exception: Prior treatment for NMIBC with intravesical instillation therapy such as BCG or intravesical chemotherapy is permitted, but must be completed ≥28 days before the first dose of the trial drug.
Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC
Cannot have received: antineoplastic treatment for MIBC
Exception: Prior treatment for NMIBC with intravesical instillation therapy such as BCG or intravesical chemotherapy is permitted, but must be completed ≥28 days before the first dose of the trial drug. Prior systemic treatment received for treatment of NMIBC is not permitted.
Has received prior pelvic/local radiation therapy or any antineoplastic treatment for MIBC
Cannot have received: anti-PD-1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-PD-L2 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: checkpoint inhibitor
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Cannot have received: antibody-drug conjugate (ASG-22CE, other MMAE-containing ADCs)
Has received prior therapy with an ASG-22CE or other MMAE-containing ADCs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05879653 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage MIBC or N0M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages